bodies relative to the pre-treatment standard is indicates that the treatment is not working and a decrease in XMRV genome sequences or anti-XMRV antibodies relative to a pre-treatment standard indicates a treatment is working. [0049] It is understood that the sample can comprise any biological substance from a subject such as a nucleic acid, peptide, polypeptide, or tissue sample.